Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide.

Roche MI, Lu Z, Hui JH, Sharon J.

Hybridoma (Larchmt). 2011 Feb;30(1):19-28. doi: 10.1089/hyb.2010.0083.

2.

The binding sites of monoclonal antibodies to the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide.

Lu Z, Rynkiewicz MJ, Yang CY, Madico G, Perkins HM, Wang Q, Costello CE, Zaia J, Seaton BA, Sharon J.

Immunology. 2013 Nov;140(3):374-89. doi: 10.1111/imm.12150.

3.

Antibodies to both terminal and internal B-cell epitopes of Francisella tularensis O-polysaccharide produced by patients with tularemia.

Lu Z, Perkins HM, Sharon J.

Clin Vaccine Immunol. 2014 Feb;21(2):227-33. doi: 10.1128/CVI.00626-13. Epub 2013 Dec 18.

4.

Functional and structural characterization of Francisella tularensis O-antigen antibodies at the low end of antigen reactivity.

Lu Z, Rynkiewicz MJ, Yang CY, Madico G, Perkins HM, Roche MI, Seaton BA, Sharon J.

Monoclon Antib Immunodiagn Immunother. 2014 Aug;33(4):235-45. doi: 10.1089/mab.2014.0022.

5.

Protective B-cell epitopes of Francisella tularensis O-polysaccharide in a mouse model of respiratory tularaemia.

Lu Z, Madico G, Roche MI, Wang Q, Hui JH, Perkins HM, Zaia J, Costello CE, Sharon J.

Immunology. 2012 Jul;136(3):352-60. doi: 10.1111/j.1365-2567.2012.03589.x.

6.

Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide.

Rynkiewicz MJ, Lu Z, Hui JH, Sharon J, Seaton BA.

Biochemistry. 2012 Jul 17;51(28):5684-94. Epub 2012 Jul 2.

7.

Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge.

Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, Shlomchik MJ, Herzenberg LA, Herzenberg LA, Vogel SN.

Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4343-8. doi: 10.1073/pnas.0813411106. Epub 2009 Feb 26.

8.

A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides.

Wang Q, Shi X, Leymarie N, Madico G, Sharon J, Costello CE, Zaia J.

Biochemistry. 2011 Dec 20;50(50):10941-50. doi: 10.1021/bi201450v. Epub 2011 Nov 28.

9.
10.

Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.

Kim TH, Pinkham JT, Heninger SJ, Chalabaev S, Kasper DL.

J Infect Dis. 2012 Apr 1;205(7):1056-65. doi: 10.1093/infdis/jir620. Epub 2011 Oct 3.

11.
12.

[Species- and genus-specific antigenic epitopes of Francisella tularensis lipopolysaccharides].

Pavlovich NV, Aronova NV, Onoprienko NN, Sorokin VM, Mazrukho BL.

Mol Gen Mikrobiol Virusol. 2000;(3):7-12. Russian.

PMID:
10975073
13.

[The determination of the antigenic determinant of protective monoclonal antibodies specific to the Francisella tularensis lipopolysaccharide].

Khlebnikov VS, Golovlev IR, Tokhtamysheva NV, Averin SF, Kulevatskiĭ DP, Grechko GK, Averina AA, Vetchinin SS.

Zh Mikrobiol Epidemiol Immunobiol. 1993 Jan-Feb;(1):83-8. Russian.

PMID:
7520655
14.

Production and characterization of a monoclonal antibody to Francisella tularensis lipopolysaccharide.

Gubbins MJ, Berry JD, Schmidt L, Cabral T, Kabani A, Tsang RS.

Hybridoma (Larchmt). 2007 Apr;26(2):98-103.

PMID:
17451358
15.

Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.

Cole LE, Mann BJ, Shirey KA, Richard K, Yang Y, Gearhart PJ, Chesko KL, Viscardi RM, Vogel SN.

J Leukoc Biol. 2011 Oct;90(4):787-97. doi: 10.1189/jlb.0111014. Epub 2011 Jul 12.

16.

Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis.

Apicella MA, Post DM, Fowler AC, Jones BD, Rasmussen JA, Hunt JR, Imagawa S, Choudhury B, Inzana TJ, Maier TM, Frank DW, Zahrt TC, Chaloner K, Jennings MP, McLendon MK, Gibson BW.

PLoS One. 2010 Jul 6;5(7):e11060. doi: 10.1371/journal.pone.0011060.

17.

Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Savitt AG, Mena-Taboada P, Monsalve G, Benach JL.

Clin Vaccine Immunol. 2009 Mar;16(3):414-22. doi: 10.1128/CVI.00362-08. Epub 2009 Jan 28.

18.

Immunotherapy of tularemia: characterization of a monoclonal antibody reactive with Francisella tularensis.

Narayanan RB, Drabick JJ, Williams JC, Fortier AH, Meltzer MS, Sadoff JC, Bolt CR, Nacy CA.

J Leukoc Biol. 1993 Jan;53(1):112-6.

PMID:
8426087
19.

Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity.

Cole LE, Elkins KL, Michalek SM, Qureshi N, Eaton LJ, Rallabhandi P, Cuesta N, Vogel SN.

J Immunol. 2006 Jun 1;176(11):6888-99.

20.

Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS.

Sandström G, Sjöstedt A, Johansson T, Kuoppa K, Williams JC.

FEMS Microbiol Immunol. 1992 Oct;5(4):201-10.

PMID:
1419118

Supplemental Content

Support Center